|

HP518 - Dose Escalation Clinical Trials

1 actively recruiting trial

Also known as: Part 1 - Dose Escalation

Pipeline

Phase 1/2: 1

Top Sponsors

  • Hinova Pharmaceuticals Inc.1

Indications

  • Metastatic Castration-resistant Prostate Cancer1
  • Cancer1

Other1 trial

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.